Alembic Pharmaceuticals announces USFDA Final Approval for Betamethasone Valerate Foam, 0.12%

Alembic Pharmaceuticals Limited (Alembic) today announced that it has received final approval from the US Food & Drug Administration (USFDA) for its Abbreviated New Drug Application (ANDA) Betamethasone Valerate Foam, 0.12%. The approved ANDA is therapeutically equivalent to the reference listed drug product (RLD), Luxiq Foam, 0.12%, of Norvium Bioscience, LLC (Norvium). Betamethasone valerate foam, 0.12% is a medium potency topical corticosteroid indicated for relief of the inflammatory and pruritic manifestations of corticosteroid-responsive dermatoses of the scalp. Refer label for a detailed indication.

Alembic has a cumulative total of 213 ANDA approvals (185 final approvals and 28 tentative approvals) from USFDA.

Shares of Alembic Pharmaceuticals Limited was last trading in BSE at Rs. 1100.55 as compared to the previous close of Rs. 1117.35. The total number of shares traded during the day was 3607 in over 408 trades.

The stock hit an intraday high of Rs. 1135.00 and intraday low of 1097.00. The net turnover during the day was Rs. 3992566.00.

Source : Equity Bulls

Keywords

AlembicPharmaceuticals INE901L01018 USFDA FinalAPproval ANDA BetamethasoneValerateFoam